Retrometabolic drug design

Retrometabolic drug design is a strategy in pharmacology and drug design that aims to improve the safety and effectiveness of medicinal drugs. This approach involves designing drugs that are metabolized into active compounds after administration, rather than being active in their original form.

Overview

The concept of retrometabolic drug design was first proposed by Albert I. Meyers in the 1980s. The idea is to design a drug that is initially inactive, but becomes active after being metabolically transformed in the body. This approach can potentially reduce the risk of adverse effects and improve the therapeutic index of the drug.

Process

The process of retrometabolic drug design involves several steps:

1. Identification of the active metabolite: The first step is to identify the active metabolite that will be the final product of the drug's metabolism. This metabolite should have the desired therapeutic effect and minimal toxicity.
2. Design of the soft drug: The next step is to design a "soft drug" that will be metabolically converted into the active metabolite. This involves modifying the structure of the active metabolite to create a prodrug that is inactive but can be metabolized into the active form.
3. Evaluation of the soft drug: The soft drug is then evaluated in preclinical and clinical studies to assess its safety, efficacy, and metabolic profile.

Advantages and Disadvantages

Advantages of retrometabolic drug design include:

• Improved safety: By designing drugs that are inactive until metabolized, the risk of adverse effects can be reduced.
• Targeted delivery: The active metabolite can be delivered to specific tissues or cells, improving the drug's effectiveness.

Disadvantages include:

• Complexity: The process of designing and evaluating soft drugs is complex and time-consuming.
• Unpredictable metabolism: The metabolic transformation of the soft drug into the active metabolite can be unpredictable, potentially leading to variable therapeutic effects.

Examples

Examples of drugs designed using the retrometabolic approach include loteprednol etabonate, a corticosteroid used to treat eye inflammation, and remdesivir, an antiviral drug used to treat COVID-19.

See also

• Prodrug
• Drug metabolism
• Pharmacokinetics

‎